Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLIFE SOLUTIONS INCBLFS · Entity 4614 | Chief Quality and Operations | March 23, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLIFE SOLUTIONS INC
Report date March 23, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,758 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Sale · Disposed 2,577 · Balance 108,758 F1: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 31, 2026 21:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,577 | $19.17 | $49,401.09 |
DisclosureSEC source: 0001628280-26-022501 · wk-form4_1774991982.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,758 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 1,907 | $19.12 | $36,461.84 |
DisclosureSEC source: 0001628280-26-020576 · wk-form4_1774300110.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 9, 2026 22:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 500 | $20.00 | $10,000.00 |
DisclosureSEC source: 0001628280-26-016165 · wk-form4_1773094257.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,242 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 22:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 96,923 | $20.15 | $1,952,998.45 |
DisclosureSEC source: 0001628280-26-016165 · wk-form4_1773094257.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,742 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 418 | $20.74 | $8,669.32 |
DisclosureSEC source: 0001628280-26-015341 · wk-form4_1772748626.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,665 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 13,013 | $22.65 | $294,744.45 |
DisclosureSEC source: 0001628280-26-012469 · wk-form4_1772146509.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,083 F2 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 32,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012469 · wk-form4_1772146509.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,096 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 335 | $25.59 | $8,572.65 |
DisclosureSEC source: 0001628280-26-001385 · wk-form4_1767909860.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,984 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 09, 2025 Filed Dec 17, 2025 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 519 | $25.13 | $13,042.47 |
DisclosureSEC source: 0001628280-25-057719 · wk-form4_1766010343.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,319 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 415 | $26.74 | $11,097.10 |
DisclosureSEC source: 0001628280-25-054280 · wk-form4_1764369320.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,838 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 21:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 419 | $27.36 | $11,463.84 |
DisclosureSEC source: 0001628280-25-045015 · wk-form4_1760477418.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,253 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 511 | $26.83 | $13,710.13 |
DisclosureSEC source: 0001683151-25-000003 · wk-form4_1757970140.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,672 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 413 | $25.44 | $10,506.72 |
DisclosureSEC source: 0001628280-25-041303 · wk-form4_1756415242.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,183 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 400 | $22.27 | $8,908.00 |
DisclosureSEC source: 0001628280-25-034684 · wk-form4_1752098067.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,596 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 320 | $23.70 | $7,584.00 |
DisclosureSEC source: 0001628280-25-031097 · wk-form4_1749763422.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,996 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 251 | $22.46 | $5,637.46 |
DisclosureSEC source: 0001628280-25-028708 · wk-form4_1748642829.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,316 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 286 | $20.11 | $5,751.46 |
DisclosureSEC source: 0001628280-25-017585 · wk-form4_1744408136.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,567 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,869 | $22.66 | $178,311.54 |
DisclosureSEC source: 0001628280-25-016634 · wk-form4_1743716886.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,853 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 29,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,722 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 19,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,011 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,331 | $25.00 | $33,275.00 |
DisclosureSEC source: 0001628280-25-012678 · wk-form4_1741901158.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,912 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 324 | $25.46 | $8,249.04 |
DisclosureSEC source: 0001628280-25-010566 · wk-form4_1741212823.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,243 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:46 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 78 | $26.54 | $2,070.12 |
DisclosureSEC source: 0001628280-25-005842 · wk-form4_1739573206.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,567 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 00:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 328 | $27.02 | $8,862.56 |
DisclosureSEC source: 0001628280-25-000983 · wk-form4_1736381429.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,645 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 22:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 252 | $27.20 | $6,854.40 |
DisclosureSEC source: 0001628280-24-049476 · wk-form4_1732919366.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,973 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 23:38 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 66 | $26.34 | $1,738.44 |
DisclosureSEC source: 0001628280-24-047994 · wk-form4_1731627476.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,225 F1 · shares: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 277 | $23.15 | $6,412.55 |
DisclosureSEC source: 0001628280-24-044813 · wk-form4_1730502101.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,291 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-23 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 267 | $25.12 | $6,707.04 |
DisclosureSEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 3 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,568 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 21, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 96 | $25.61 | $2,458.56 |
DisclosureSEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,835 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 18, 2024 Filed Sep 18, 2024 21:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 240 | $22.50 | $5,400.00 |
DisclosureSEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,931 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 408 | $21.78 | $8,886.24 |
DisclosureSEC source: 0001628280-24-026084 · wk-form4_1717189544.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,171 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 17, 2024 Filed May 21, 2024 12:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 85 | $22.18 | $1,885.30 |
DisclosureSEC source: 0001628280-24-024446 · wk-form4_1716293584.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,579 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 23:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 481 | $15.31 | $7,364.11 |
DisclosureSEC source: 0001628280-24-017498 · wk-form4_1713914077.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,664 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 395 | $17.99 | $7,106.05 |
DisclosureSEC source: 0001628280-24-013828 · wk-form4_1711748356.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,145 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,177 | $16.60 | $85,938.20 |
DisclosureSEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 4 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,540 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 319 | $17.42 | $5,556.98 |
DisclosureSEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 3 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,717 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,036 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,591 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 87 | $17.35 | $1,509.45 |
DisclosureSEC source: 0001628280-24-006705 · wk-form4_1708728647.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,940 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,198 | $16.76 | $20,078.48 |
DisclosureSEC source: 0001628280-24-001985 · wk-form4_1706049023.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,027 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 601 | $16.75 | $10,066.75 |
DisclosureSEC source: 0001628280-24-000470 · wk-form4_1704405875.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality and Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,225 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 17, 2023 Filed Dec 19, 2023 22:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-042030 · wk-form4_1703026465.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,568 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| December 03, 2023 Filed Dec 21, 2023 20:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-042481 · wk-form4_1703191474.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,826 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 466 | $12.37 | $5,764.42 |
DisclosureSEC source: 0001628280-23-040677 · wk-form4_1701735316.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,340 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 19, 2023 Filed Dec 5, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-040677 · wk-form4_1701735316.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,806 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 15:41 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 114 | $10.77 | $1,227.78 |
DisclosureSEC source: 0001628280-23-039100 · wk-form4_1700062902.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,539 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 05, 2023 Filed Nov 13, 2023 21:41 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-038654 · wk-form4_1699911667.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,653 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| October 22, 2023 Filed Oct 24, 2023 23:46 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-035029 · wk-form4_1698191164.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,354 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| October 08, 2023 Filed Oct 10, 2023 21:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034201 · wk-form4_1696973135.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,019 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 568 | $14.16 | $8,042.88 |
DisclosureSEC source: 0001628280-23-033511 · wk-form4_1696280929.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,767 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.